1 2 aim

Marketing authorization in Japan of VILTEPSO®

NS Pharma announced today that the Ministry of Health, Labour and Welfare (MHLW) has approved VILTEPSO® Intravenous Infusion 250 mg (viltolarsen, previously NS-065/NCNP- 01) for the treatment of patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping therapy. This represents the first regulatory approval for viltolarsen in the world and the first approved DMD treatment other than steroids in Japan.

Read the official news release by Nippon Shinyaku here